{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:57:17Z","timestamp":1793303837754,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00749-3","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:15:24Z","timestamp":1745993724000},"page":"1105-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment"],"prefix":"10.1007","volume":"14","author":[{"given":"Katherine","family":"Gunther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Profeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medina","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenzie","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-214X","authenticated-orcid":false,"given":"David R.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/104.3.589","volume":"104","author":"AE Harding","year":"1981","unstructured":"Harding AE. Friedreich\u2019s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104:589\u2013620.","journal-title":"Brain"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/archneur.65.10.1296","volume":"65","author":"M Pandolfo","year":"2008","unstructured":"Pandolfo M. Friedreich ataxia. Arch Neurol. 2008;65:1296\u2013303.","journal-title":"Arch Neurol"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","volume":"335","author":"A Durr","year":"1996","unstructured":"Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, et al. Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia. N Engl J Med. 1996;335:1169\u201375.","journal-title":"N Engl J Med"},{"key":"749_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.006","volume":"18","author":"C Rummey","year":"2020","unstructured":"Rummey C, Farmer JM. Lynch DR Predictors of loss of ambulation in Friedreich\u2019s ataxia. EClinicalMedicine. 2020;18: 100213.","journal-title":"EClinicalMedicine"},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307:46\u20139.","journal-title":"J Neurol Sci"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.1073\/pnas.0912925107","volume":"107","author":"DR Richardson","year":"2010","unstructured":"Richardson DR, Lane DJ, Becker EM, Huang ML, Whitnall M, SuryoRahmanto Y, et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A. 2010;107:10775\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/ng1097-215","volume":"17","author":"A R\u00f6tig","year":"1997","unstructured":"R\u00f6tig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215\u20137.","journal-title":"Nat Genet"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2015.01.010","volume":"21","author":"A Martelli","year":"2015","unstructured":"Martelli A, Schmucker S, Reutenauer L, Mathieu JRR, Peyssonnaux C, Karim Z, et al. Iron regulatory protein 1 sustains mitochondrial iron loading and function in frataxin deficiency. Cell Metab. 2015;21:311\u201323.","journal-title":"Cell Metab"},{"key":"749_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.111","volume":"7","author":"R Abeti","year":"2016","unstructured":"Abeti R, Parkinson MH, Hargreaves IP, Angelova PR, Sandi C, Pook MA, et al. Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich\u2019s ataxia. Cell Death Dis. 2016;7: e2237.","journal-title":"Cell Death Dis"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","volume":"96","author":"R Lodi","year":"1999","unstructured":"Lodi R, Cooper JM, Bradley JL, Manners D, Styles P, Taylor DJ, Schapira AH. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A. 1999;96:11492\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","volume":"17","author":"C Strawser","year":"2017","unstructured":"Strawser C, Schadt K, Hauser L, McCormick A, Wells M, Larkindale J, Lin H, Lynch DR. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17:895\u2013907.","journal-title":"Expert Rev Neurother"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14737175.2024.2310617","volume":"24","author":"DR Lynch","year":"2024","unstructured":"Lynch DR, Perlman S, Schadt K. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations. Expert Rev Neurother. 2024;24:251\u20138.","journal-title":"Expert Rev Neurother"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acn3.51897","volume":"111","author":"DR Lynch","year":"2024","unstructured":"Lynch DR, Goldsberry A, Rummey C, Farmer J, Boesch S, Delatycki MB, Giunti P, Hoyle JC, Mariotti C, Mathews KD, Nachbauer W, Perlman S, Subramony SH, Wilmot G, Zesiewicz T, Weissfeld L, Meyer C. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann Clin Transl Neurol. 2024;111:4\u201316.","journal-title":"Ann Clin Transl Neurol"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A, Hoyle JC, Mariotti C, Mathews KD, Nachbauer W, O\u2019Grady M, Perlman S, Subramony SH, Wilmot G, Zesiewicz T, Meyer CJ. Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. 2023;38:313\u201320.","journal-title":"Mov Disord"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, Giunti P, Wilmot G, Zesiewicz T, Perlman S, Goldsberry A, O\u2019Grady M, Meyer CJ. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89:212\u201325.","journal-title":"Ann Neurol"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","volume":"6","author":"DR Lynch","year":"2018","unstructured":"Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O\u2019Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018;6:15\u201326.","journal-title":"Ann Clin Transl Neurol"},{"key":"749_CR17","doi-asserted-by":"crossref","unstructured":"D'Oria V, Petrini S, Travaglini L, Priori C, Piermarini E, Petrillo S, Carletti B, Bertini E, Piemonte F. Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons .Int J Mol Sci. 2013;14:7853\u201365.","DOI":"10.3390\/ijms14047853"},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1089\/ars.2012.4537","volume":"19","author":"Y Shan","year":"2013","unstructured":"Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, IodiCarstens M, Carstens EE, Pook MA, Cortopassi GA. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19:1481\u201393.","journal-title":"Antioxid Redox Signal"},{"key":"749_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004253","volume":"4","author":"V Paupe","year":"2009","unstructured":"Paupe V, Dassa EP, Goncalves S, Auch\u00e8re F, L\u00f6nn M, Holmgren A, Rustin P. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS ONE. 2009;4: e4253.","journal-title":"PLoS ONE"},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fncel.2018.00188","volume":"12","author":"R Abeti","year":"2018","unstructured":"Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich\u2019s Ataxia Models. Front Cell Neurosci. 2018;12:188.","journal-title":"Front Cell Neurosci"},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1212\/WNL.0000000000200913","volume":"99","author":"C Rummey","year":"2022","unstructured":"Rummey C, Corben LA, Delatycki M, Wilmot G, Subramony SH, Corti M, et al. Natural history of Friedreich ataxia: heterogeneity of neurologic progression and consequences for clinical trial design. Neurology. 2022;99:e1499\u2013510.","journal-title":"Neurology"},{"key":"749_CR22","doi-asserted-by":"publisher","unstructured":"Zahir H, Murai M, Wu L, Valentine M, Hynes S. Clinical assessment of the drug-drug interaction potential of omaveloxolone in healthy adult participants. J Clin Pharmacol. Published online February 7, 2025. https:\/\/doi.org\/10.1002\/jcph.6189","DOI":"10.1002\/jcph.6189"},{"key":"749_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","volume":"20","author":"MP Chin","year":"2014","unstructured":"Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014;20:953\u20138.","journal-title":"J Card Fail"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00749-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:57:52Z","timestamp":1747663072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00749-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Lynch receives grants from Reata\/Biogen pharmaceuticals for performance of the MOXIE and planned studies of omaveloxolone. He also receives grants from Larimar, PTC, Neurocrine, Solid Biosciences, the NIH, FDA, FARA and MDA. Katherine Gunther, Victoria Profeta, Medina Keita, Courtney Park, McKenzie Wells, Sonal Sharma, and Kimberly Schadt have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved through the CHOP IRB as study 2609 and performed in accordance with the Helsinki Declaration of 1964. All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}